Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Experts discuss rapid changes in cancer treatment and in the management of infections that can accompany these therapies.
Natural killer cells may be potentially powerful, but not fully understood, immune system cancer fighters.
As an eligibility barrier cracks, a lung cancer patient gets a new lease on life.
Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.
Researchers from Johns Hopkins Kimmel Cancer Center pilot multidisciplinary approach for addressing immunotherapy-related toxicities.
Even positive breaking news looks different to people who know the reality of a hard-to-treat cancer.
T\ogether, these trials indicate that triple combos show promise and while there are significant toxicities, they are mostly manageable.
New immunotherapy option approved for uncommon, aggressive type of lung cancer.
Healing—the word is related to “wholeness”—isn’t measurable, but it’s nevertheless essential.
A long and successful battle with melanoma has left Dan Engel a new and different man.
A new type of immunotherapy shows promising activity against cancers caused by human papillomavirus (HPV).
Changing gut bacteria to improve treatment response may be the next frontier in immunotherapy.
A Phase II trial tested SurVaxM in combination with standard therapy for the aggressive brain cancer.
First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.
The results of the study are huge and challenge the standard of care.
Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.